Interpretation of Multiple Myeloma Guidelines update (version 2， 2023) of National Comprehensive Cancer Network （NCCN）
Multiple myeloma (MM) is the second most common hematological malignancy. With the continuous advent of new drugs, the survival of MM patients has been significantly improved, with a median survival of 7-10 years. However, the overall survival of high-risk MM patients is still less than 3 years, and...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Diagnostics Concepts & Practice
2023-04-01
|
| Series: | Zhenduanxue lilun yu shijian |
| Subjects: | |
| Online Access: | https://www.qk.sjtu.edu.cn/jdcp/fileup/1671-2870/PDF/1693470179760-763771897.pdf |